WO2023214238A1 - Formulations et procédés d'élimination directe du sodium chez des patients souffrant d'insuffisance cardiaque et/ou de dysfonctionnement rénal sévère - Google Patents

Formulations et procédés d'élimination directe du sodium chez des patients souffrant d'insuffisance cardiaque et/ou de dysfonctionnement rénal sévère Download PDF

Info

Publication number
WO2023214238A1
WO2023214238A1 PCT/IB2023/054061 IB2023054061W WO2023214238A1 WO 2023214238 A1 WO2023214238 A1 WO 2023214238A1 IB 2023054061 W IB2023054061 W IB 2023054061W WO 2023214238 A1 WO2023214238 A1 WO 2023214238A1
Authority
WO
WIPO (PCT)
Prior art keywords
infusate
dsr
sodium
patient
regimen
Prior art date
Application number
PCT/IB2023/054061
Other languages
English (en)
Inventor
Jeffrey TESTANI
Christopher MCINTYRE
Ian CROSBIE
Oliver Goedje
Original Assignee
Sequana Medical Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US17/661,737 external-priority patent/US11559618B2/en
Application filed by Sequana Medical Nv filed Critical Sequana Medical Nv
Publication of WO2023214238A1 publication Critical patent/WO2023214238A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/718—Starch or degraded starch, e.g. amylose, amylopectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A61K31/78—Polymers containing oxygen of acrylic acid or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
    • A61M1/28—Peritoneal dialysis ; Other peritoneal treatment, e.g. oxygenation
    • A61M1/287—Dialysates therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock

Definitions

  • the present invention relates generally to formulations for, and methods of, using low or sodium-free infusates that are administered to a patient’s peritoneal cavity to remove sodium and excess fluid from the body to alleviate fluid overload (“DSR therapy”).
  • DSR therapy fluid overload
  • U.S. Patent No. 10,918,778 B2 describes DSR infusates and methods of use for removing excess fluid by the removal of sodium from heart failure patients having residual renal function.
  • the DSR infusates are specially formulated to be instilled into a patient’s peritoneal cavity to remove sodium and water through one or both of: 1) ultrafiltration and/or 2) diffusion of sodium ions down a steep concentration gradient between the infusate instilled into patient’s peritoneal cavity and surrounding tissues and vessels.
  • sodium and ultrafiltrate After sodium and ultrafiltrate accumulates in the peritoneal cavity, it may be drained in accordance with conventional peritoneal dialysis methods, or more preferably, transferred by an implantable pump to the patient’s urinary bladder, from which it is subsequently voided.
  • U.S. Patent No. 5,589, 197 to Shockley et al. describes a dialysate for use in peritoneal dialysis, wherein the sodium concentration is between about 35 to 125 meq/L. As discussed in that patent, such solutions may be used to transport sodium to the peritoneal cavity for subsequent removal. Problems encountered with early experience with such low sodium dialysates, included symptomatic drops in blood pressure, and dialysis disequilibrium syndrome, a potentially fatal complication resulting in cerebral edema, coma and death.
  • compositions, and methods of use for expanding the benefits of DSR therapy to patients suffering from severe renal dysfunction.
  • DSR infusates and methods of use are provided for removing sodium and reducing fluid overload in patients with severe renal dysfunction, while aiding maintenance of stable serum sodium levels.
  • patient groups include patients who exhibit chronic kidney disease (“CKD”) of Stage 4 or Stage 5, and who in addition to kidney disease also may manifest with any of several forms of heart failure treatable by body fluid management.
  • CKD chronic kidney disease
  • Applicants have observed that instilling low or no sodium infusates into the peritoneal cavities of patients with residual renal function can significantly alleviate the symptoms of heart failure by reducing fluid overload.
  • DSR formulations that comprise a sterile solution of dextrose in a range of 5 to 15 weight percent, with no or low sodium concentrations, resulted in removal of significant amounts of sodium (e.g., up to 2 gm) and fluid (e.g., up to 2 liter) during a two-hour dwell time.
  • those patients’ blood serum sodium levels remained substantially constant.
  • the amount of sodium and water removed during a specified dwell period will be function of the concentration of sodium in the infusate, the osmolality of the infusate, and the tendency of constituents of the infusate to migrate across through the peritoneum and into the patient’s tissue and vascular system. For example, an infusate with no sodium will create a steep gradient that causes sodium to migrate to the peritoneal cavity, whereas an infusate with a sodium concentration approaching isomolar with blood serum levels, e.g., 130 meq/ml, will create a much shallower gradient. Sodium will move to the fluid in the peritoneal cavity asymptotically until that gradient disappears and the sodium concentration in the fluid in the peritoneal cavity becomes isotonic, provided the dwell period is sufficiently long.
  • the osmolality of the infusate will determine its ability to drive water to the peritoneal cavity, and will vary based on the constituent in the infusate and its ability to migrate across the peritoneum. For example, it is known that dextrose provides high osmolality when a dextrose containing infusate is instilled into the peritoneal cavity. However, because the dextrose molecules to quickly migrate from the peritoneal cavity, the ability of the infusate to drive ultrafiltrate to the peritoneal cavity will decline fairly rapidly. By comparison, an icodextrin solution also provides high initial osmolality, remains high throughout the dwell period because the icodextrin molecules are less prone to migrate.
  • the ability of the infusate to drive excess fluid into the patient’s peritoneal cavity also will determine the ability of the DSR infusate to move excess sodium and water to the peritoneal cavity for subsequent removal.
  • the more water that is drawn to the peritoneal cavity the greater the amount of sodium that will migrate to the peritoneal cavity to render the sodium concentration isotonic.
  • a regimen of DSR infusates having different compositions may be provided for sequential use with patients having severe renal dysfunction.
  • a first infusate composition may have a first selected no or low sodium concentration, and may be instilled into a patient’ s peritoneal cavity in an amount from 0.25 L to 1.5 L or more to initiate DSR treatment to reduce fluid and sodium overload to establish a new fluid and sodium equilibrium for the patient.
  • a second infusate composition having a different composition, may be instilled in an amount of 0.25 L to 2.0 L to remove additional amounts of fluid and sodium to establish a new fluid equilibrium for the patient.
  • Treatment with these solutions may be serial, or coordinated, and/or interspersed, with the patient’s conventional hemodialysis or peritoneal dialysis regime.
  • an exemplary first DSR infusate may comprise a no or low sodium solution, preferably consisting of sterile water containing 5 weight percent dextrose and up to 40 weight percent icodextrin. In particular, a higher concentration of icodextrin is expected to be desirable to avoid hyperglycemia.
  • the patient may undergo a second DSR therapy session, during which additional sodium and/or excess fluid may be removed, but in different proportions than during the first therapy session.
  • One exemplary composition for use as a second DSR infusate may comprise a no or low sodium solution consisting of sterile water containing 5 weight percent dextrose and 15 weight percent icodextrin. More generally, during the subsequent DSR therapy session, which may be temporally contiguous with the first session, any of a range of infusates having different dextrose and icodextrin concentrations of between about 5 weight percent and 40 weight percent may be used to target remove of fluid or enhanced sodium depuration as indicated on a patient-specific basis.
  • serum sodium concentration may be sampled, e.g., via blood samples, to confirm that the serum sodium level does not drop precipitously.
  • a conventional hemodialysis or peritoneal dialysis session may be conducted between the first and second DSR sessions, or shortly thereafter, to further rebalance and stabilize the patient’s serum sodium and fluid levels.
  • the DSR infusates may be instilled into, and ultrafiltrate removed from, the peritoneal cavity using conventional peritoneal dialysis tubing sets. More preferably, removal of dialysate solution and sodium-laden ultrafiltrate may be accomplished with the implantable pump system described in commonly-assigned U.S. Patent No. 9,956,336, the contents of which are incorporated herein by reference. That patent describes a system for ambulatory peritoneal dialysis in which a dialysate is infused into the peritoneal cavity. After a predetermined time and/or at predetermined intervals, an implantable pump transfers fluid accumulated in the peritoneum to the patient’s bladder, where it may be excreted by urination. BRIEF DESCRIPTION OF THE DRAWINGS
  • FIG. 1 is a perspective view of an exemplary regimen of infusates having compositions selected in accordance with the principles of the present invention for reducing fluid and sodium overload in patients with severe renal dysfunction.
  • FIG. 2 is a plan view of exemplary components of an implantable pump system for use in conjunction with the infusate compositions and methods of the present invention.
  • FIG. 3 is a schematic view of an exemplary arrangement for practicing the DSR therapy methods of the present invention using the implantable device of the system of FIG. 2.
  • FIG. 4 illustrates steps of an exemplary method of using the DSR regimen of FIG. 1 in accordance with the principles of the present invention.
  • FIGS. 5A, 5B and 5C are graphs depicting the results of testing of the inventive DSR method on an initial group of five animals.
  • FIGS. 6A to 6F are graphs depicting the results of testing of the inventive DSR method on a follow-up group of ten animals.
  • FIGS. 7A to 7C are graphs depicting changes to blood volume, red blood count, and plasma volume for a sub-group of the second group of animals after consecutive applications of the inventive DSR method.
  • FIGS. 8A and 8B are, respectively, graphs showing the amounts of sodium removed in a first in-human (“FIM”) trial for 10 patients using a single dose of sodium-free 10 weight percent dextrose solution and a conventional peritoneal dialysis solution, sequentially administered via a conventional peritoneal dialysis catheter, as a function of dwell time, and sodium removal comparisons for each patient.
  • FIM first in-human
  • FIGS. 9A and 9B are, respectively, bar charts that compare average observed changes in physiologic parameters for 10 other human patients during a second trial in which patients underwent DSR sessions three times a week for six weeks with a DSR solution of sodium-free 10 weight percent dextrose solution.
  • FIGS. 10A, 10B and 10C are, respectively, graphs showing the evolution of observed changes in physiologic parameters for the 10 patients during the second human trial.
  • FIG. 11 is a bar chart showing the improvement in diuretic response in the second trial.
  • FIG. 12 is a table showing a durable effect post DSR-treatment for patients who experienced a substantial reduction in need for diuretic drugs following the second trial.
  • the present invention is directed to infusate compositions and methods of treating fluid and/or sodium overload in patients with severe renal dysfunction, e.g., CKD stage 4 or stage 5.
  • the infusate compositions and treatment methods are expected to be complimentary to conventional hemodialysis or peritoneal dialysis treatments and methods.
  • Methods and compositions for treating heart failure patients suffering from fluid overload that have residual renal function are described in U.S. Patent No. 10,918,778 B2, which is incorporated herein by reference in its entirety.
  • the present invention is directed to methods and compositions that extend the benefits of direct sodium removal technology to patients with severe renal dysfunction.
  • the methods and compositions of the present invention are expected not only to improve sodium/fluid balance, but also to improve renal function and efficacy of loop diuretics used to control fluid overload.
  • a regimen consisting of at least a first DSR infusate composition having a selected osmolality and no or low sodium.
  • the first infusate may comprise sterile water, up to 40 wt% icodextrin, and up to 10 wt% dextrose.
  • the regimen also may include a second infusate composition having the same or different composition and sodium concentration.
  • An exemplary second infusate, which may be used in a follow-up DSR session, may comprise sterile water, 15 wt% icodextrin, and 5 wt% dextrose.
  • Other DSR infusates may omit dextrose entirely and consist solely of a low-sodium icodextrin concentration, or have as constituents other high molecule weight biocompatible polymers.
  • the first infusate may be constituted so that when instilled into a patient’s peritoneal cavity, it creates gradients that cause both high amounts of water and sodium to migrate to infusate during a first dwell period.
  • the infusate, ultrafiltrate and sodium are removed from the peritoneal cavity using a conventional peritoneal drainage catheter, or more preferably, an implanted pump that transfers the fluid to the patient’s bladder.
  • a second infusate for use in a subsequent DSR treatment may be constituted so that when instilled into the patient’s peritoneal cavity, it creates gradients that cause additional water and/or sodium to migrate to the peritoneal cavity during a second dwell period.
  • the second infusate, ultrafiltrate and sodium may be removed from the peritoneal cavity using a conventional drainage catheter or an implanted pump.
  • the osmolality, constituents and sodium concentration of the second infusate may be adjusted as required on a patient-specific basis to tailor relief desired for that patient.
  • the DSR infusate regimen is designed to be used in coordination with a patient’s regular hemodialysis or peritoneal dialysis schedule.
  • Conventional dialysis treatments both hemodialysis and peritoneal dialysis, target removal of blood-borne toxins and waste by-products.
  • conventional dialysis techniques can remove some excess water from the patient’s circulation, it is not uncommon for patients with severe renal dysfunction to suffer from fluid overload.
  • DSR therapy may be used in combination with conventional dialysis techniques to remove sodium, resolve fluid overload, and reduce congestion.
  • DSR therapy may restore some degree of kidney function, improve the efficacy of loop diuretics and mitigate some degree of transient dialysis-induced kidney injury.
  • a zero or low sodium concentration in each infusate causes sodium and fluid (osmotic ultrafiltrate) to pass from the patient’s body into the peritoneal cavity.
  • the DSR infusate is allowed to remain, or dwell, in the peritoneal cavity for a specified period before it is removed, together with the extracted sodium and the osmotic ultrafiltrate. Removal of the sodium-laden DSR infusate and osmotic ultrafiltrate from the peritoneal cavity may be performed using an implantable system, such as the Alfapump commercialized by Sequana Medical NV of Zwijnaarde, Belgium.
  • a no or low sodium DSR infusate has a sodium content of less than 120 meq/L, and more preferably, less than 35 meq/L, and includes infusates having zero or only trace amounts of sodium.
  • the fluid overload treatment methods of the present invention specifically contemplate use of the inventive methods in patients experiencing severe kidney dysfunction, e.g., CKD Stage 4 or Stage 5, function and also in heart failure patients with end-stage renal disease.
  • FIG. 1 in accordance with the principles and methods of the present invention, an exemplary regimen 10 of DSR infusates suitable for use with patients with severe renal dysfunction is described, and includes two formulations designed to be instilled into a patient’s peritoneal cavity having different osmolalities, intended for successive DSR sessions.
  • FIG.l depicts bag 12 of DSR Solution 1, which may be employed in a first treatment session, and bag 14 of DSR Solution 2, which may be used in a follow-up DSR session as described below. It should be understood, however, that DSR Solution 1 and Solution 2 may consist of a single composition of DSR infusate.
  • conventional tubing set 16 for use in infusing the fluid of either bag 12 or 14 into the peritoneal cavity of a patient using a conventional peritoneal dialysis catheter (not shown).
  • DSR Solution 1 and DSR Solution 2 are infusates that may have different compositions and are intended for sequential use in patients having severe renal dysfunction. Preferably, such patients regularly undergo conventional hemodialysis or peritoneal dialysis.
  • DSR Solution 1 may have a sodium concentration and osmolality selected for initiating DSR treatment, to reduce fluid and sodium overload.
  • DSR Solution 2 may have a different sodium concentration and osmolality, and may be used in a subsequent DSR session to further reduce fluid and sodium levels achieved with the first DSR session. It expected that one or more DSR sessions may be coordinated, and/or interspersed, with the patient’s conventional hemodialysis or peritoneal dialysis regime.
  • the patient may undergo one or more conventional hemodialysis or peritoneal dialysis sessions to remove blood-borne toxins. Thereafter, the patient may undergo a subsequent session using DSR Solution 2 to further reduce fluid and/or stored sodium, or to maintain the fluid/sodium balance achieved after the session with DSR Solution 1.
  • DSR Solution 1 may comprise a no or low sodium solution consisting of sterile water containing 5 to 10 weight percent dextrose and up to 40 weight percent icodextrin. Such an exemplary composition of DSR Solution 1 is expected to remove both sodium and water. Thereafter, the patient may undergo a further DSR therapy session with DSR Solution 2, such that the composition of DSR Solution 2 is selected either to remove additional fluid and/or sodium or to maintain a new fluid/sodium balance achieved after the first DSR session.
  • An exemplary composition for DSR Solution 2 may comprise a no or low sodium solution consisting of sterile water containing 5 weight percent dextrose and 15 weight percent icodextrin. Such an exemplary composition of DSR Solution 2 is expected preferentially to remove more sodium than water, relative to DSR Solution 1.
  • serum sodium concentration may be periodically sampled, e.g., via blood samples, to monitor the patient’s serum sodium level.
  • Conventional hemodialysis or peritoneal dialysis sessions may be conducted after or between the first and any second DSR sessions, as generally required for patients with severe renal dysfunction.
  • it is expected that such conventional hemodialysis or peritoneal dialysis sessions also may be used to fine-tune and/or stabilize the patient’s fluid management.
  • formulations suitable for first and follow-up DSR sessions may contain from zero to 50 grams of dextrose per 100 ml of aqueous solution, and for some applications 5 to 10 weight percent dextrose; from 0.5 to 50 grams of icodextrin per 100 ml of aqueous solution and more preferably 15 to 30 weight percent icodextrin.
  • Suitable solutions also may employ high molecular weight biocompatible polymer solutions (weight average molecular weight Da > 10,000) having from 0.5 to 50 grams of high molecular weight polymer per 100 ml of aqueous solution, and combinations thereof.
  • Additional constituents that may be substituted for the dextrose and/icodextrin include solutions containing between 0.5 and 50 grams of one or more of: xylitol, glycerol, hyperbranched polyglycerol, sorbitol, carnitine, taurine, amino acids, urea, polyacrylate, polyethyleneimine, and stevioside per 100 ml aqueous solution.
  • the aqueous solution contains at least purified water, and in addition may include electrolytes such as low amounts of magnesium or calcium salts, preservatives, ingredients having antimicrobial or antifungal properties, or buffering materials to control pH of the infusate.
  • Icodextrin compositions generally may be preferable to dextrose compositions as icodextrin has been observed to experience a lower rate of uptake when employed in a peritoneal dialysis setting, and thus better preserves the peritoneal membrane compared to dextrose-based compositions.
  • the regimen of infusates described herein may be specifically formulated to treat patients with CKD Stage 4 or Stage 5, especially patients for whom loop diuretics are no longer effective.
  • the assignee s initial human testing with a no sodium dextrose solution suggests that interspersing DSR therapy sessions with conventional hemodialysis or peritoneal dialysis sessions enables the latter sessions advantageously to be used to monitor and/or adjust fluid and sodium levels.
  • the methods of present invention for using the DSR compositions of the invention optionally may include monitoring a patient’s blood serum sodium level in connection with the DSR sessions.
  • a blood sample may be taken during or after DSR session to monitor serum sodium level.
  • use a first DSR infusate may cause more sodium than water to migrate to the patient’s peritoneal cavity, which ultrafiltrate together with the infusate and sodium, may be drained from the peritoneal cavity via a conventional peritoneal dialysis catheter or more preferably, using the implantable pump described in the above-incorporated patent. Thereafter, the patient may undergo conventional hemodialysis or peritoneal dialysis, during which additional fluid may be removed to rebalance the patient’s sodium metabolism.
  • DSR session may be intended to additional water and/or sodium to migrate to the patient’s peritoneal cavity. It has been theorized that, as observed during initial testing, the body may store excess sodium in extravascular spaces, such as interstitially in the vessel walls.
  • the methods and DSR regimes of the present invention may be performed with conventional peritoneal infusion and drainage catheters, it is expected that use the implantable pump system offered by the assignee of the present application may be particularly advantageous.
  • the Alfapump system offered by Sequana Medical NV, is well suited for removing sodium-laden infusate and ultrafiltrate from a patient’s peritoneal cavity.
  • the implantable pump may be activated, in accordance with a clinician’s programmed instructions, to pump the sodium-laden DSR infusate and ultrafiltrate to the patient's bladder for subsequent voiding.
  • fluid may continue to accumulate in the peritoneal cavity, and the implantable pump may be programmed to pump such fluid to the bladder on a periodic basis.
  • the methods of the present invention therefore provide a method of controlling fluid overload and edema in patients with severe renal dysfunction, while permitting such patients to experience a more normal lifestyle, other than their regularly scheduled dialysis sessions. And because the inventive methods and compositions are expected to lead to a reduction in fluid and/or sodium volume, the patient may not only experience improved comfort and lifestyle, but also delayed onset of other co-morbidities, such as further advancement of chronic kidney disease and/or progressive heart failure.
  • System 100 includes implantable pump 120 that is specially configured to move fluid out of the peritoneal cavity and into the bladder, and includes a plurality of sensors for monitoring and recording operating parameters relevant to the health of the patient.
  • External charging and communication system 130 is used to periodically charge and communicate with implantable device 110, and downloads operational data from device 110.
  • Monitoring and control system 140 includes software installed on a treating physician's computer to receive the operational data from charging and communication system 130, and allow the physician to modify the operation of implantable device 110 based on the physician's perception of the patient's health based on review of the operational data uploaded from device 110.
  • the monitoring and control system may be configured to alert the physician as to a prediction or detection of infection, heart failure decompensation or other clinical events based on the recorded operating parameters.
  • Implantable device 110 optionally may also include one or more ultraviolet (UV) sources configured to inhibit infection.
  • UV ultraviolet
  • charging and communication system 130 may be coupled, either wirelessly or using a cable, to monitoring and control system 140 to download for review data stored on implantable device 120, or to adjust the operational parameters of the implantable device.
  • Monitoring and control system 140 also may be configured to upload and store date retrieved from charging and communication system 130 to a remote server (not shown) for later access by the physician or charging and communications system 130.
  • Implantable device 120 comprises an electromechanical pump having housing 121 configured for subcutaneous implantation.
  • Implantable device 120 preferably includes an electrically-driven mechanical gear pump having connectors 122 and 124.
  • Bladder catheter 125 is coupled to pump housing 121 via connector 124.
  • Peritoneal catheter 123 is coupled to pump housing 121 via connector 122.
  • Peritoneal catheter 123 comprises a tube having a first (proximal) end configured to be coupled to pump housing 121 and a second (distal) end configured to be positioned in the peritoneal cavity.
  • Bladder catheter 125 comprises a tube having a first (proximal) end configured to be coupled to pump housing 121 and a second (distal) end configured to be inserted through the wall of, and fixed within, a patient's bladder.
  • both catheters are made of medical-grade silicone and include polyester cuffs at their distal ends (not shown) to maintain the catheters in position.
  • Implantable device 120 also may include pressure sensors that monitor pressure in one or both of the peritoneal cavity and the bladder, such that fluid is pumped from the peritoneal cavity to the bladder if the intra-abdominal pressure exceeds a limit determined by the physician. Alternatively, or in addition, the output of the pressure sensors may interrupt pumping of fluid to the bladder until the bladder is determined to have sufficient space to accommodate additional fluid. For patient comfort, implantable device 120 optionally may be programmed not to pump at night or when an accelerometer included in the implantable device indicates that the patient is asleep (and thus unlikely to be able to void the bladder). Implantable device 120 preferably includes multiple separate fail-safe mechanisms, to ensure that urine cannot pass from the bladder to the peritoneal cavity through the pump, thereby reducing the risk of transmitting infection.
  • External charging and communication system 130 includes base 131 and handpiece 132.
  • handpiece 132 contains a controller, a radio transceiver, an inductive charging circuit, a battery, a quality-of-charging indicator and a display, and is removably coupled to base 131 to recharge its battery.
  • Base 131 may contain a transformer and circuitry for converting conventional 120V or 220-240 V service to a suitable DC current to charge handpiece 132 when coupled to base 131.
  • handpiece 132 may include such circuitry and a detachable power cord, thereby permitting the handpiece to be directly plugged into a wall socket to charge the battery.
  • each of implantable device 120 and handpiece 132 includes a device identifier stored in memory, such that handpiece 132 provided to the patient is coded to operate only with that patient's specific implantable device 120.
  • Handpiece 132 preferably includes housing 133 having multi-function button 134, display 135, a plurality of light emitting diodes (LEDs, not shown) and inductive coil portion 136.
  • Multi-function button 134 provides the patient the ability to issue a limited number of commands to implantable device 120, while display 135 provides visible confirmation that a desired command has been input; it also displays battery status.
  • Inductive coil portion 136 houses an inductive coil that is used transfer energy from handpiece 132 to recharge the battery of implantable device 120.
  • the LEDs which are visible through the material of housing 133 when lit, may be arranged in three rows of two LEDs each, and are coupled to the control circuitry and inductive charging circuit contained within handpiece 132.
  • the LEDs may be arranged to light up to reflect the degree of inductive coupling achieved between handpiece 132 and implantable device 120 during recharging of the latter. Alternatively, the LEDs may be omitted and an analog display provided on display 135 indicating the quality of inductive coupling.
  • Control circuitry contained within handpiece 132 is coupled to the inductive charging circuit, battery, LEDs and radio transceiver, and includes memory for storing information from implantable device 120.
  • Handpiece 132 also preferably includes a data port, such as a USB port, that permits the handpiece to be coupled to monitoring and control system 140 during visits by the patient to the physician's office.
  • handpiece 132 may include a wireless chip, e.g., conforming to the Bluetooth or IEEE 802.11 wireless standards, thereby enabling the handpiece to communicate wirelessly with monitoring and control system 140, either directly or via the Internet.
  • Monitoring and control system 140 is intended primarily for use by the physician and comprises software configured to run on a conventional computer, e.g., a laptop as illustrated in FIG. 2 or tablet or smartphone.
  • the software enables the physician to configure, monitor and control operation of charging and communication system 130 and implantable device 120.
  • the software may include routines for configuring and controlling pump operation, such as a target amount of fluid to move daily or per motor actuation, intervals between pump actuation, and limits on peritoneal cavity pressure, bladder pressure, pump pressure, and battery temperature.
  • System 140 also may provide instructions to implantable device 120 via charging and control system 130 to control operation of implantable device 120 so as not to move fluid during specific periods (e.g., at night) or to defer pump actuation if the patient is asleep.
  • System 140 further may be configured, for example, to send immediate commands to the implantable device to start or stop the pump, or to operate the pump in reverse or at high power to unblock the pump or associated catheters.
  • the software of system 140 also may be configured to download real-time data relating to pump operation, as well as event logs stored during operation of implantable device 120. Based on the downloaded data, e.g., based on measurements made of the patient's intra-abdominal pressure, respiratory rate, and/or fluid accumulation, the software of system 140 optionally may be configured to alert the physician to a prediction or detection of a change in the patient's health for which an adjustment to the flow rate, volume, time and/or frequency of pump operation may be required.
  • system 140 optionally may be configured to remotely receive raw or filtered operational data from a patient's handpiece 132 over a secure Internet channel. Further details of system 100 are describe in the above-incorporated U.S. patent.
  • FIG. 3 depicts implantable device 110 implanted within a patient’s abdomen with the distal end of peritoneal catheter 123 disposed within the patient’s peritoneal cavity PC and the distal end of bladder catheter 125 disposed in the patient’s bladder B.
  • Reservoir 150 of a first or second DSR solution is coupled to peritoneal infusion catheter 152 to deliver DSR solution from reservoir 150 into peritoneal cavity PC.
  • Optional pump 148 may be coupled to infusion catheter 152 to accelerate instillation of DSR solution into the peritoneal cavity PC, or pump 148 may be omitted so that solution is infused via gravity.
  • implantable device 120 is configured to move sodium-laden DSR infusate and osmotic ultrafiltrate from the peritoneal cavity to the bladder in quantities, intervals and flow rates selected to provide sufficient time for targeted amounts of sodium and/or fluid to accumulate in the DSR infusate.
  • Treatment algorithms may be developed for the different DSR formulations and instilled volumes, different lengths of dwell period and different rates of removal to the bladder, to optimize serum sodium level as well as patient comfort.
  • pumping fluid from the peritoneal cavity for short but frequent intervals is expected to inhibit the accumulation of material on the interior lumens of catheters 123 and 125, and reduce the risk of tissue ingrowth.
  • the fluid circuit of implantable device 120 may be configured to provide an average flow rate of between about 1 to 2.5 liters/hour, although much higher and lower flow rates are possible if needed.
  • the pumping time, flow rate and volume, including the time the DSR infusate is allowed to remain in the peritoneal cavity, may be programmed by the physician using monitoring and control system 40 as required for a specific patient.
  • FIG. 4 describes an initial or follow-up DSR session, e.g., with DSR Solution or 2, as may be prescribed for on a patientspecific basis.
  • Method 200 begins with instilling a DSR Solution in an amount of 0.25 liter to 1.5 liter or more into the peritoneal cavity of a patient from a reservoir, e.g., infusion bag 12 or 14 of FIG. 1 at step 201, using an external pump or gravity.
  • the DSR solution is permitted to remain in the peritoneal cavity for a specified dwell time, such as 2 hours, to cause excess sodium and fluid to migrate from the patient’s body to the peritoneal cavity.
  • a specified dwell time such as 2 hours
  • the patient’s serum sodium level optionally may be sampled to monitor the sodium level.
  • expiration of the dwell time may be determined if the patient experiences discomfort from overextension of the abdomen.
  • step 204 upon completion of the dwell time, sodium-laden DSR solution and ultrafiltrate is moved from the patient’s body via a conventional peritoneal drainage catheter or by pumping it to the bladder using an implantable pump as described with respect to FIG. 2. If the fluid and sodium is pumped to the bladder, it may be excreted when the bladder is voided. Either way, removal of the DSR solution and ultrafiltrate reduces the amount of fluid and sodium from the body.
  • step 205 which may be a regularly scheduled dialysis session, the patient undergoes conventional hemodialysis or peritoneal dialysis to remove accumulated metabolic wastes and toxins.
  • additional fluid or sodium may be removed to rebalance any residual fluid/sodium disequilibrium arising from the first DSR session.
  • the physician also may reassess the patient’s need for loop diuretics, and make an appropriate adjustment in dosing a general assessment of the patient’s health is conducted, including reduction in edema or fluid overload, cardiac and renal function, and serum sodium level.
  • an additional DSR session may be conducted using DSR Solution 2, and steps 202 to 206 repeated.
  • the patient may undergo one or more follow-up DSR sessions at step 207.
  • the goal of these sessions may be to retain the renal improvements achieved from the initial DSR session, and/or to draw down additional amounts of non-osmotic sodium, as discussed above.
  • additional DSR sessions may periodically be scheduled to maintain patient health improvements resulting from the first and any prior follow-up DSR sessions.
  • the physician may choose to revise the composition of the DSR infusate to titrate its ability to remove fluid and sodium specific to the needs of the patient. In this manner, it is expected that the physician may be able to prolong the benefits achieved during the prior DSR treatments, including reduced fluid overload, improved renal function and/or improved efficacy of loop diuretics, if still required. It is further hypothesized that a patient suffering endstage renal disease who undergoes the regimen described above may arrest or possibly even reverse the course of the disease.
  • the DSR infusate generally comprised purified water and dextrose, e.g., 10 grams per 100 ml of water, and was allowed to dwell in their peritoneal cavities for up to six hours. 5-25 micro curies of 1-131 radiolabeled albumin was mixed into the infusate as a non-absorbable tracer to determine ultrafiltration kinetics without requiring serial drains of the abdomen.
  • the fluid in the peritoneal cavities was sampled to determine total sodium removed and sodium concentration in the fluid accumulating in the peritoneal cavity as a function of time, and blood samples were taken as well. Specifically, in the 1-1/2 hours after infusion of the DSR infusate, 3 ml blood sample and 2.5 ml fluid samples were taken every 15 minutes and analyzed. In the next 1-1/2 hour period, blood and fluid samples were taken every F2 hour. And in the final 3 hours, additional blood and fluid samples were taken every hour. In addition, the total volume of fluid accumulated in the peritoneal cavity, consisting of sodium-laden DSR infusate and osmotic ultrafiltrate, was recorded as a function of time.
  • FIG. 5A shows the total amount of sodium removed as a function of dwell time for the first group of pigs
  • FIG. 5B shows the sodium concentration in the samples removed from the peritoneal cavities as a function of time
  • FIG. 5C depicts the total volume of fluid accumulated in the peritoneal cavities of the first group of pigs. As shown in FIG. 5C, after two hours, infusion of 1 liter of DSR infusate induced about 1 liter of osmotic filtrate to accumulate in the peritoneal cavity.
  • a second group of ten pigs (“protocol pigs”), 1 liter of DSR infusate was infused in the peritoneal cavities of each pig for a two-hour dwell period.
  • serum sodium, serum osmolality, plasma osmolality and glucose levels of the pigs were periodically measured by taking 6 ml blood samples every F2 hour.
  • Total osmolality, glucose osmolality and non-glucose osmolality of the fluid accumulating in the peritoneal cavities were periodically measured during the dwell period using the foregoing samples.
  • FIG. 6A is a chart showing the total fluid volume removed from the peritoneal cavity of each protocol pig after a two-hour dwell.
  • FIG. 6B shows the total amount of sodium removed from the peritoneal cavity of each protocol pig after a two-hour dwell.
  • FIG. 6C shows the evolution of total osmolality, glucose osmolality, and non-glucose osmolality for samples of fluid from the peritoneal cavities of the protocol pigs throughout the two-hour dwell period.
  • FIGS. 6D, 6E and 6F show the evolution of serum sodium, serum osmolality, and serum glucose, respectively, for the protocol pigs throughout the two-hour dwell period.
  • DSR infusates can remove a clinically relevant amount of sodium, e.g., about 4 g, with a single administration of 1 liter of DSR infusate and a two-hour dwell, but with clinically negligible impact on serum sodium levels. That amount of removed sodium is generally equivalent to two days of recommended sodium consumption, which will induce the elimination of stored fluid via urination and direct removal of a significant ( 1 liter with the studied parameters) accumulation of osmotic ultrafiltrate from the peritoneal cavity.
  • the single administration of DSR infusate with a two-hour dwell is expected to be very safe, as serum sodium level and serum osmolality remained stable throughout the period with only an expected and clinically manageable increase of serum glucose concentration.
  • FIGS. 7A-7C depicts the measurements for a number of blood volume markers in a sub-group of five of the protocol pig population both before and after repeated application of a 10 weight percent dextrose DSR solution.
  • FIG. 7A shows almost a 1/2 reduction in the total blood volume of the protocol pigs after five cycles of DSR treatment.
  • FIG. 7B shows virtually no impact of the DSR method on the total volume of red blood cells.
  • FIG. 7C shows that there is a reduction in plasma volume of approximately 60%. Accordingly, as depicted in FIGS. 7A-7C, repeated use of a DSR solution can achieve a significant reduction in blood volume by reducing plasma volume. This also demonstrates that a DSR solution can be used to eliminate different levels of fluid overload.
  • the assignee of the present invention sought and obtained permission from an investigational review board to conduct a first trial to assess the feasibility of removing sodium from patients with a single dose of DSR solution, and a second follow-up study to assess safety and tolerance to serial DSR sessions.
  • the first trial was conducted with ten patients who with end-stage renal disease who regularly underwent peritoneal dialysis with pre-existing peritoneal catheters.
  • the DSR solution was instilled via subcutaneous ports and after a dwell time, removed via an implantable pump as described with respect to FIG. 2.
  • a DSR solution of 10 weight percent dextrose in sterile water as a peritoneal infusate. The details and results of these initial trials are described with respect to FIGS. 8 through 11.
  • Inclusion criteria were the following: actively undergoing peritoneal dialysis with a functioning peritoneal dialysis catheter implanted less than 3 years, patient age greater than 18 years and judged by the treating nephrologist to be at or above optimal volume status (i.e., not dehydrated).
  • Exclusion criteria were uncontrolled diabetes mellitus with frequent episodes of severe hyperglycemia; systolic blood pressure ⁇ 100 mm Hg; serum sodium ⁇ 130 mEq/L; one or more episodes of peritonitis in the previous 6 months or active infection of the peritoneal dialysis catheter; anemia with hemoglobin ⁇ 8 g/dL; serum bicarbonate ⁇ 18 mEq/L; anuric renal failure; inability to give written informed consent or to follow the study protocol; and pregnant or lactating.
  • a 4.25% dextrose peritoneal dialysis solution was selected as the comparison solution because it is the most effective marketed peritoneal dialysis solution for fluid/ sodium removal and has an osmolarity similar to that of 10% dextrose.
  • the intraperitoneal volume was determined longitudinally using the indicator dilution technique with I-131-radiolabeled albumin (Daxor Inc), in addition to direct measurement of drained fluid at the end of the dwell. Vital signs, blood (every 30 minutes), and peritoneal fluid (every 15 minutes) were obtained serially throughout the protocol. Patients in the DSR group were given 50% of the ultrafiltration volume back at the end of the dwell in the form of intravenous normal saline to replace sodium/volume losses. The primary end point was safety/tolerability, defined as completion of the 2-hour dwell without significant discomfort or adverse events. The secondary efficacy end point was the difference in sodium removal between the DSR solution and standard peritoneal dialysis solution.
  • Serum sodium was not different between groups. Removal of off-target nonsodium electrolytes with DSR such as potassium (5.5 ⁇ 1.1 mmol), magnesium (1.7 ⁇ 2.5 mmol), phosphorus (1.9 ⁇ 0.6 mmol), and calcium (1.6 ⁇ 0.3 mmol) was negligible, and plasma electrolyte and chemistry parameters were stable throughout the dwell. As shown in FIG. 8A, the secondary efficacy outcome of superior sodium removal with sodium-free 10% dextrose (4.5 ⁇ 0.4g) compared with standard peritoneal dialysis solution (1.0 ⁇ 0.3g) was met (P ⁇ 0.001). In addition to a substantially higher average sodium clearance, the consistency of sodium removal was excellent.
  • the absolute variability between individual patients’ sodium removal and the average sodium removal was similar between DSR and standard peritoneal dialysis solution, as depicted in FIG. 8B. However, because the total sodium removed in standard peritoneal dialysis solution was substantially lower, the relative variability between individuals was much higher with standard peritoneal dialysis solution, ranging from 8% to 75% of the average total sodium removal compared with 2% to 18% in patients receiving DSR. Fluid removal was also greater with sodium-free 10% dextrose, also with a high degree of consistency across patients.
  • the primary finding from the first human trial is that substantial sodium removal via the peritoneal membrane is feasible.
  • the DSR therapy was well tolerated, with limited effect on plasma electrolyte levels, minimal off-target solute removal, and freedom from discomfort in the majority of human participants.
  • the sodium removal was scalable, with substantially larger quantities of sodium removed by increasing the volume of 10% dextrose cycled into the peritoneal space.
  • nt-proBNP > 400 pg/ml (or BNP > 100 pg/ml) and oral diuretic dose > 80mg furosemide equivalents
  • Oral diuretic dose > 120mg furosemide equivalents
  • the second study ran for a total of 6 weeks, plus a two-week follow-up. After screening, ten patients were implanted with the Alfapump® implantable pump described in FIG. 2 about two weeks prior to initiation of the trial. Three days before the DSR trial was begun, each patient was given an intravenous administration of 40 mg of furosemide, followed by a 6- hour timed urine collection. At the outset of the DSR trial, all loop diuretics were stopped. During the following two weeks, the patients were resident in-hospital with diets controlled at 3 grams of sodium per day for the first week and 5 grams of sodium the second week. Patients then were permitted to return home.
  • the patients underwent DSR sessions three times a week using a 10 weight percent dextrose DSR solution.
  • the patients again underwent a diuretic challenge with intravenous administration of 40 mg of furosemide, followed by a 6-hour timed urine collection.
  • FIGS. 9 to 12 Results of the study are presented in FIGS. 9 to 12.
  • the study participants experienced a significant reduction in measured N-terminal- pro B-type natriuretic peptide (“NT-proBNP”) and creatinine levels, indicating improvement in cardio-renal function.
  • FIGS. 10A, 10B and 10C depict the temporal trends of improvement for the study patients over the six-week period.
  • FIG. 11 depicts improvement in the patients’ response to loop diuretic between the trial outset and after six weeks of DSR sessions, showing a 3-fold increase in urine output.
  • FIG. 12 is a table reporting the results of follow-up evaluations with eight of the patients in the study, and indicates that the effect of the DSR therapy in reducing diuretic resistance was durable, with patients experiencing a reduction between 89% and 50% of their daily diuretic dosing at 10 to 12 months following their last DSR session, with at least one patient ceasing the use of a diuretic entirely.
  • the second human study therefore demonstrated that six weeks of DSR therapy, using an implantable pump to remove the DSR solution and ultrafiltrate, was overall well tolerated and successfully maintained a neutral sodium balance and stable body weight, despite complete withdraw of loop diuretics.
  • the study also showed significant benefit to cardio-renal function, as observed by meaningful improvement in NT-proBNP and renal function.
  • diuretic resistance substantially and durably improved.
  • pump system 1 may be ordered differently and may include additional or fewer components of various sizes and composition.
  • the appended claims are intended to cover all such changes and modifications that fall within the true spirit and scope of the invention.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Anesthesiology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • External Artificial Organs (AREA)

Abstract

La présente invention concerne un régime lié à une solution intraveineuse pour l'élimination directe du sodium ("DSR") et des procédés d'utilisation, lesquels sont destinés à éliminer le sodium et à réduire la surcharge de liquide chez des patients souffrant de dysfonctionnement rénal sévère et/ou d'insuffisance cardiaque, régime et procédés dans lesquels un patient a au moins une première session de DSR avec une première solution intraveineuse de DSR sans sodium ou à faible teneur en sodium qui est instillée dans la cavité péritonéale du patient pendant une première période inactive pour faire migrer le sodium et l'excès de liquide vers la cavité péritonéale du patient, et ensuite, le patient peut subir une dialyse classique pour rééquilibrer les niveaux de liquide et de sodium du patient.
PCT/IB2023/054061 2022-05-02 2023-04-21 Formulations et procédés d'élimination directe du sodium chez des patients souffrant d'insuffisance cardiaque et/ou de dysfonctionnement rénal sévère WO2023214238A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US17/661,737 US11559618B2 (en) 2017-05-24 2022-05-02 Formulations and methods for direct sodium removal in patients having severe renal dysfunction
US17/661,737 2022-05-02
US18/157,741 2023-01-20
US18/157,741 US11844890B2 (en) 2017-05-24 2023-01-20 Formulations and methods for direct sodium removal in patients having heart failure and/or severe renal dysfunction

Publications (1)

Publication Number Publication Date
WO2023214238A1 true WO2023214238A1 (fr) 2023-11-09

Family

ID=86382931

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2023/054061 WO2023214238A1 (fr) 2022-05-02 2023-04-21 Formulations et procédés d'élimination directe du sodium chez des patients souffrant d'insuffisance cardiaque et/ou de dysfonctionnement rénal sévère

Country Status (1)

Country Link
WO (1) WO2023214238A1 (fr)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5589197A (en) 1993-10-04 1996-12-31 Baxter International, Inc. Low sodium peritoneal dialysis solution
WO2017176687A1 (fr) * 2016-04-04 2017-10-12 Medtronic, Inc. Système de dialyse péritonéale régénératif
US9956336B2 (en) 2012-02-15 2018-05-01 Sequana Medical Ag Methods of using a fluid management system
WO2018215917A1 (fr) * 2017-05-24 2018-11-29 Sequana Medical Ag Procédé, solution et appareil d'élimination directe de sodium permettant de réduire une surcharge de fluide chez des patients atteints d'insuffisance cardiaque
US11559618B2 (en) 2017-05-24 2023-01-24 Sequana Medical Nv Formulations and methods for direct sodium removal in patients having severe renal dysfunction

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5589197A (en) 1993-10-04 1996-12-31 Baxter International, Inc. Low sodium peritoneal dialysis solution
US5631025A (en) * 1993-10-04 1997-05-20 Baxter International Inc. Low sodium peritoneal dialysis solution
US9956336B2 (en) 2012-02-15 2018-05-01 Sequana Medical Ag Methods of using a fluid management system
WO2017176687A1 (fr) * 2016-04-04 2017-10-12 Medtronic, Inc. Système de dialyse péritonéale régénératif
WO2018215917A1 (fr) * 2017-05-24 2018-11-29 Sequana Medical Ag Procédé, solution et appareil d'élimination directe de sodium permettant de réduire une surcharge de fluide chez des patients atteints d'insuffisance cardiaque
US10918778B2 (en) 2017-05-24 2021-02-16 Sequana Medical Nv Direct sodium removal method, solution and apparatus to reduce fluid overload in heart failure patients
US11559618B2 (en) 2017-05-24 2023-01-24 Sequana Medical Nv Formulations and methods for direct sodium removal in patients having severe renal dysfunction
US11602583B2 (en) 2017-05-24 2023-03-14 Sequana Medical Nv Direct sodium removal method, solution and apparatus to reduce fluid overload in heart failure patients

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
HECKING MKAINZ AHORL WHHERKNER HSUNDER-PLASSMANN G.: "Sodium setpoint and odium gradient: influence on plasma sodium change and weight gain", AMERICAN JOURNAL OF NEPHROLOGY, vol. 33, no. 1, 2011, pages 39 - 48
MC CAUSLAND FRBRUNELLI SMWAIKAR SS.: "Dialysate odium, serum odium and mortality in maintenance hemodialysis", NEPHROLOGY DIALYSIS TRANSPLANTATION, vol. 27, no. 4, 2012, pages 1613 - 8
MUNOZ MENDOZA JSUN SCHERTOW GMORAN JDOSS SSCHILLER B.: "Dialysate odium and sodium gradient in maintenance hemodialysis: a neglected sodium restriction approach?", NEPHROLOGY DIALYSIS TRANSPLANTATION, vol. 26, no. 4, 2011, pages 1281 - 7
NAKAYMA: "Clinical Effect of Low Na Concentration Dialysate (120 mEqlL) for CAPD Patients", PD CONFERENCE
ZEPEDA-OROZCO DQUIGLEY R.: "Dialysis disequilibrium syndrome", PEDIATRIC NEPHROLOGY, vol. 27, no. 12, 2012, pages 2205 - 2211

Similar Documents

Publication Publication Date Title
US11844890B2 (en) Formulations and methods for direct sodium removal in patients having heart failure and/or severe renal dysfunction
CN111315427B (zh) 减少心力衰竭患者体内液体超负荷的直接钠移除方法、溶液和装置
EP1753437B1 (fr) Solutions a base de bicarbonate pour dialyse peritoneale
Scribner et al. Long-term total parenteral nutrition: the concept of an artificial gut
US6287608B1 (en) Method and apparatus for treatment of congestive heart failure by improving perfusion of the kidney by infusion of a vasodilator
US7053059B2 (en) Dialysis solutions with reduced levels of glucose degradation products
JP2018529414A (ja) 腹膜限外濾過を実行するための装置
Diaz-Buxo Continuous cyclic peritoneal dialysis
Nosé et al. Therapeutic and physiological artificial heart: future prospects
WO2023214238A1 (fr) Formulations et procédés d&#39;élimination directe du sodium chez des patients souffrant d&#39;insuffisance cardiaque et/ou de dysfonctionnement rénal sévère
Diaz-Buxo et al. Experience with intermittent peritoneal dialysis and continuous cyclic peritoneal dialysis
Castro et al. How can we advance in renal replacement therapy techniques?
Misra et al. Peritoneal dialysis in diabetic end-stage renal disease
JP7034933B2 (ja) 透析濃縮液
RU2530759C1 (ru) Способ детоксикации организма
JP5735568B2 (ja) ペットの腎不全治療用の組み合わせ薬剤
JPH02196724A (ja) 腹膜透析液
Verrina et al. Technical aspects of the peritoneal dialysis procedure
Yusuf et al. Recent updates in artificial kidney technology: Potential parsing for universal coverage burden of chronic kidney disease in Indonesia
Lo Effect of PD solutions on patient outcome
Khanna et al. Continuous Ambulatory Peritoneal Dialysis in Diabetic End Stage Renal Disease
Misra et al. Peritoneal Dialysis in Diabetic End-Stage Kidney Disease
Oishi et al. Physical activity in patients undergoing automated and continuous ambulatory peritoneal dialysis: A cross-sectional study
Colombi A Review of the Clinical Evaluation of Dialysis
Khanna et al. Continuous ambulatory peritoneal dialysis in uremic diabetics

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23724023

Country of ref document: EP

Kind code of ref document: A1